A treatment of Eli Lilly has shown in a large clinical trial to slow the cognitive decline related to Alzheimer's disease. The clinical trial, which included 1,200 participants who had not yet reached an advanced stage of the disease, showed a 35 percent reduction in cognitive decline in patients treated with donanemab.
Eli Lilly plans to file an application for authorization with the U.S. Food and Drug Administration (FDA) as early as this quarter, and worldwide "as soon as possible"